|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
The present study aimed to evaluate the impact of the new TSPO ligands on mitochondrial dysfunction in a cellular model of AD-related tauopathy (human neuroblastoma cells SH-SY5Y stably overexpressing the P301L-mutant Tau) presenting mitochondrial impairments, including a decreased ATP synthesis and mitochondrial membrane potential, as well as a decrease in pregnenolone synthesis compared to control cells.
|
31536662 |
2020 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Interestingly, reduced nuclear mSREBP-2 was only found in animal models of tauopathies such as 3XTg AD mice and P301L Tau Tg mice but not in CRND8 APP transgenic mice, suggesting that tau alterations likely are involved in the changes of mSREBP-2 distribution and activation in AD.
|
30515907 |
2019 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the present study, we aimed to characterize the link between ER stress and bioenergetics defects under normal condition (human SH-SY5Y neuroblastoma cells: control cells) or under pathological AD condition [SH-SY5Y cells overexpressing either the human amyloid precursor protein (APP) or mutant tau (P301L)].
|
30683981 |
2019 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
The present study evaluates the impact of neurosteroids belonging to the sex hormone family (progesterone, estradiol, estrone, testosterone, 3α-androstanediol) on mitochondrial dysfunction in cellular models of AD: human neuroblastoma cells (SH-SY5Y) stably transfected with constructs encoding (1) the human amyloid precursor protein (APP) resulting in overexpression of APP and Aβ, (2) wild-type tau (wtTau), and (3) mutant tau (P301L), that induces abnormal tau hyperphosphorylation.
|
26198711 |
2016 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
To investigate the effect of early immune modulation on neuroinflammation and cognitive outcome, we treated triple transgenic Alzheimer's disease mice (harboring PS1(M146V), APP(Swe), and tau(P301L) transgenes) with the small molecule tumor necrosis factor-α inhibitors, 3,6'-dithiothalidomide and thalidomide, beginning at four months of age.
|
22632257 |
2012 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
A triple transgenic mouse model of AD (3xTg-AD) which harbors mutations in three human transgenes, APP(Swe), PS1(M146V) and Tau(P301L), was used in these experiments.
|
21237293 |
2011 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
We previously demonstrated that 3xTg-AD mice, which harbor the human amyloid precursor protein Swedish mutant transgene, presenilin knock-in mutation, and tau P301L mutant transgene, exhibit significant alterations in overall myelination patterns and oligodendrocyte status at time points preceding the appearance of amyloid and tau pathology.
|
20696774 |
2010 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Herein, we demonstrate that triple-transgenic AD (3xTg-AD) mice, which harbor the human amyloid precursor protein Swedish mutant transgene, presenilin knock-in mutation, and tau P301L mutant transgene, exhibit significant region-specific alterations in myelination patterns and in oligodendrocyte marker expression profiles at time points preceding the appearance of amyloid and tau pathology.
|
18661556 |
2009 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
We validated this procedure using aged (15-18m) mice expressing three Alzheimer's disease-related transgenes, PS1(M146 V), APP(Swe), and tau(P301L).
|
18831990 |
2009 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.
|
17111439 |
2006 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Ageing APP-V717IxTau-P301L double tg mice (14-17 months) have combined AD-like pathology in hippocampus and cortex consisting of amyloid plaques and neurofibrillary tangles.
|
17028556 |
2006 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
To study the interaction between Abeta and tau and their effect on synaptic function, we derived a triple-transgenic model (3xTg-AD) harboring PS1(M146V), APP(Swe), and tau(P301L) transgenes.
|
12895417 |
2003 |